Table 1. Baseline characteristics of the study population, n = 581.
| Age, years | 64±9 |
| Body mass index, kg/m2 | 28±4 |
| Males | 460 (79) |
| Current smokers | 122 (21) |
| Blood pressure, systolic, mm Hg | 142±20 |
| Blood pressure, diastolic, mm Hg | 82±11 |
| Biochemistry | |
| B-Leukocytes, 109/L | 7.0±1.9 |
| B-Haemoglobin, mmol/L | 8.9±0.7 |
| B-Red blood cell count, 1012/L | 4.8±0.4 |
| B-Reticulocyte count, 109/L | 48±15 |
| B-Platelet count, 109/L | 231±59 |
| B-Immature platelet count, 109/L | 5.8 (4.4;7.9) |
| B-Immature platelet fraction, % | 2.5 (1.9;3.5) |
| B-Mean platelet volume, fL | 10.8±0.9 |
| B-Platelet distribution width, fL | 13.4±1.9 |
| B-Platelet large cell ratio, % | 32±7 |
| P-High-sensitive C-reactive protein, mg/L | 0.8 (0.4;1.6) |
| S-Interleukin-6, pg/mL | 2.2 (1.5;3.4) |
| S-Thrombopoietin, pg/mL | 45 (28;64) |
| P-Creatinine, µmol/L | 81 (71;94) |
| Cardiovascular morbidity | |
| Prior percutaneus coronary intervention | 562 (97) |
| Prior myocardial infarction | 533 (92) |
| Prior coronary artey bypass grafting | 49 (8) |
| Prior stroke | 25(4) |
| Type 2 Diabetes Mellitus | 148 (25) |
| Medication | |
| Aspirin | 581 (100) |
| Statins | 533 (92) |
| Beta-blockers | 440 (76) |
| ACE inhibitors | 265 (46) |
| Angiotensin receptor blockers | 80 (14) |
| Calcium antagonists | 111 (19) |
| Diuretics | 147 (25) |
| Proton pump inhibitors | 65 (11) |
| Insulina | 47 (32) |
| Oral antidiabetic medicationa | 129 (87) |
Data is presented as mean±SD, n(%) or median (25th;75th percentile).
a out of 148 patients with type 2 diabetes.
B: blood, S: serum, P: plasma.